Find out more about how you can promote your products at the orphan drug sector’s premier event by downloading the sponsorship brochure today.
"WODC is the key annual congress for anybody working in the rare disease arena.”
“WODC is the key annual congress for anybody working in the rare disease arena.”
“Well organised, good programme and most useful, the networking sessions.”
AlepSyr Biotech Consultancy
“The event was excellent for networking and gathering information.”
Ataxia South Wales
Despite incentives for development Korea remains dependant on imported orphan drugs Korea is one of the few countries within the APAC region which already has an implemented legislation for promoting orphan drugs research and development. The active patient community led by the Korea Organization for Rare Disease (KORD), lobbying amongst hospitals, and advanced clinical and […]
The post Korea’s Orphan Drug Pricing Policy Changes for the Better appeared first on Orphan Drugs.
Find the EMA’s orphan designation and approvals for November here. Find the FDA’s October designations here. FDA - 13/11/2014 Generic Name: stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells Trade Name: Nicord(R) Orphan Designation: Treatment of Hodgkin lymphoma Orphan Designation Status: Designated FDA Orphan Approved: Sponsor: Gambia Cell FDA - 13/11/2014 Generic Name: stem/progenitor […]
Pfizer has entered the gene therapy ring with the hiring of Professor Michael Linden, University College London, and deal with Spark Therapeutics Pfizer has announced two strategic decisions to increase their investment in rare disease research and development. To get the ball rolling, Pfizer have established an agreement with Spark therapeutics incorporating Spark’s own gene […]
The post Pfizer Enters the Gene Therapy Ring with Spark Therapeutics Tie-in appeared first on Orphan Drugs.
Strategy and innovation for the orphan drug and rare disease industry